Loading...

IQVIA Holdings

NYSE:IQV
Snowflake Description

Moderate growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IQV
NYSE
$26B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
IQV Share Price and Events
7 Day Returns
1.1%
NYSE:IQV
-2.9%
US Life Sciences
-0.7%
US Market
1 Year Returns
30.8%
NYSE:IQV
20.3%
US Life Sciences
3%
US Market
IQV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
IQVIA Holdings (IQV) 1.1% 0.5% -5.5% 30.8% 102.6% 160.9%
US Life Sciences -2.9% -4.1% -1% 20.3% 79.3% 106.4%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • IQV outperformed the Life Sciences industry which returned 20.3% over the past year.
  • IQV outperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
IQV
Industry
5yr Volatility vs Market
Related Companies

Value

 Is IQVIA Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of IQVIA Holdings to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for IQVIA Holdings.

NYSE:IQV Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 21 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.2%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NYSE:IQV
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.02
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.015 (1 + (1- 21%) (45.04%))
1.252
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.25
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.252 * 5.96%)
10.19%

Discounted Cash Flow Calculation for NYSE:IQV using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for IQVIA Holdings is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NYSE:IQV DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.19%)
2019 1,241.48 Analyst x6 1,126.64
2020 1,469.30 Analyst x6 1,210.04
2021 1,632.87 Analyst x3 1,220.34
2022 1,766.86 Est @ 8.21% 1,198.33
2023 1,882.82 Est @ 6.56% 1,158.84
2024 1,984.74 Est @ 5.41% 1,108.57
2025 2,076.20 Est @ 4.61% 1,052.38
2026 2,160.18 Est @ 4.04% 993.65
2027 2,239.03 Est @ 3.65% 934.65
2028 2,314.58 Est @ 3.37% 876.81
Present value of next 10 years cash flows $10,880.24
NYSE:IQV DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $2,314.58 × (1 + 2.73%) ÷ (10.19% – 2.73%)
$31,857.68
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $31,857.68 ÷ (1 + 10.19%)10
$12,068.28
NYSE:IQV Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $10,880.24 + $12,068.28
$22,948.53
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $22,948.53 / 197.24
$116.35
NYSE:IQV Discount to Share Price
Calculation Result
Value per share (USD) From above. $116.35
Current discount Discount to share price of $133.67
= -1 x ($133.67 - $116.35) / $116.35
-14.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of IQVIA Holdings is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for IQVIA Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are IQVIA Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NYSE:IQV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $1.23
NYSE:IQV Share Price ** NYSE (2019-05-17) in USD $133.67
United States of America Life Sciences Industry PE Ratio Median Figure of 21 Publicly-Listed Life Sciences Companies 33.93x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of IQVIA Holdings.

NYSE:IQV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:IQV Share Price ÷ EPS (both in USD)

= 133.67 ÷ 1.23

108.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IQVIA Holdings is overvalued based on earnings compared to the US Life Sciences industry average.
  • IQVIA Holdings is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does IQVIA Holdings's expected growth come at a high price?
Raw Data
NYSE:IQV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 108.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 21 Analysts
28%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 19 Publicly-Listed Life Sciences Companies 2.34x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

NYSE:IQV PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 108.38x ÷ 28%

3.86x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IQVIA Holdings is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on IQVIA Holdings's assets?
Raw Data
NYSE:IQV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $33.54
NYSE:IQV Share Price * NYSE (2019-05-17) in USD $133.67
United States of America Life Sciences Industry PB Ratio Median Figure of 37 Publicly-Listed Life Sciences Companies 4.59x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NYSE:IQV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:IQV Share Price ÷ Book Value per Share (both in USD)

= 133.67 ÷ 33.54

3.98x

* Primary Listing of IQVIA Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IQVIA Holdings is good value based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess IQVIA Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. IQVIA Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is IQVIA Holdings expected to perform in the next 1 to 3 years based on estimates from 21 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
28%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is IQVIA Holdings expected to grow at an attractive rate?
  • IQVIA Holdings's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • IQVIA Holdings's earnings growth is expected to exceed the United States of America market average.
  • IQVIA Holdings's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NYSE:IQV Future Growth Rates Data Sources
Data Point Source Value (per year)
NYSE:IQV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 21 Analysts 28%
NYSE:IQV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 21 Analysts 6%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 14.4%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NYSE:IQV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NYSE:IQV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 13,901 1,174 1
2022-12-31 13,149 2,082 1,008 1
2021-12-31 12,506 1,949 751 10
2020-12-31 11,747 1,811 561 21
2019-12-31 11,012 1,596 385 21
NYSE:IQV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 10,533 1,185 248
2018-12-31 10,412 1,254 259
2018-09-30 8,603 1,070 1,249
2018-06-30 8,475 1,162 1,277
2018-03-31 9,905 1,096 1,246
2017-12-31 9,702 970 1,277
2017-09-30 9,133 1,184 72
2017-06-30 7,804 1,008 84
2017-03-31 6,616 804 108
2016-12-31 6,815 860 72
2016-09-30 4,540 620 397
2016-06-30 4,497 643 409

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • IQVIA Holdings's earnings are expected to grow significantly at over 20% yearly.
  • IQVIA Holdings's revenue is expected to grow by 6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NYSE:IQV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below

All data from IQVIA Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:IQV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 6.75 6.75 6.75 1.00
2022-12-31 5.61 5.61 5.61 1.00
2021-12-31 4.01 4.61 3.58 5.00
2020-12-31 2.89 3.70 2.03 11.00
2019-12-31 1.93 2.49 1.58 11.00
NYSE:IQV Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 1.23
2018-12-31 1.27
2018-09-30 6.06
2018-06-30 6.10
2018-03-31 5.87
2017-12-31 5.86
2017-09-30 0.32
2017-06-30 0.42
2017-03-31 0.61
2016-12-31 0.48
2016-09-30 3.32
2016-06-30 3.39

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • IQVIA Holdings is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess IQVIA Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
IQVIA Holdings has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has IQVIA Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare IQVIA Holdings's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • IQVIA Holdings has delivered over 20% year on year earnings growth in the past 5 years.
  • IQVIA Holdings's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • IQVIA Holdings's 1-year earnings growth is negative, it can't be compared to the US Life Sciences industry average.
Earnings and Revenue History
IQVIA Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from IQVIA Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:IQV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 10,533.00 248.00 1,691.00
2018-12-31 10,412.00 259.00 1,692.00
2018-09-30 8,603.00 1,249.00 1,720.00
2018-06-30 8,475.00 1,277.00 1,687.00
2018-03-31 9,905.00 1,246.00 1,644.00
2017-12-31 9,702.00 1,277.00 1,605.00
2017-09-30 9,133.00 72.00 1,528.00
2017-06-30 7,804.00 84.00 1,345.00
2017-03-31 6,616.00 108.00 1,192.00
2016-12-31 6,815.00 72.00 1,013.00
2016-09-30 4,540.18 397.37 761.08
2016-06-30 4,496.66 408.65 785.50
2016-03-31 4,404.03 407.60 795.39
2015-12-31 4,326.00 387.00 815.00
2015-09-30 4,261.87 371.06 901.97
2015-06-30 4,229.40 352.43 889.59
2015-03-31 4,190.51 352.60 882.70
2014-12-31 4,165.00 357.00 781.00
2014-09-30 4,105.72 340.95 890.08
2014-06-30 3,977.43 315.07 870.63
2014-03-31 3,886.19 268.47 880.45
2013-12-31 3,808.34 226.59 830.21
2013-09-30 3,750.16 188.57 843.35
2013-06-30 3,731.02 173.90 836.56
2013-03-31 3,731.70 182.58 811.26
2012-12-31 3,692.30 177.55 817.76

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • IQVIA Holdings has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • IQVIA Holdings used its assets less efficiently than the US Life Sciences industry average last year based on Return on Assets.
  • IQVIA Holdings's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess IQVIA Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
IQVIA Holdings has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is IQVIA Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up IQVIA Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • IQVIA Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • IQVIA Holdings's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of IQVIA Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from IQVIA Holdings Company Filings, last reported 1 month ago.

NYSE:IQV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 6,865.00 11,876.00 991.00
2018-12-31 6,954.00 11,021.00 938.00
2018-09-30 7,460.00 10,625.00 879.00
2018-06-30 7,614.00 10,734.00 928.00
2018-03-31 8,453.00 10,453.00 1,007.00
2017-12-31 8,244.00 10,234.00 1,005.00
2017-09-30 7,507.00 9,766.00 1,147.00
2017-06-30 7,774.00 8,966.00 945.00
2017-03-31 7,800.00 8,357.00 905.00
2016-12-31 8,860.00 7,200.00 1,238.00
2016-09-30 -81.93 2,449.80 1,249.56
2016-06-30 -228.70 2,464.90 993.47
2016-03-31 -205.94 2,472.26 1,089.92
2015-12-31 -336.00 2,474.00 977.00
2015-09-30 -179.93 2,488.04 1,081.80
2015-06-30 -701.68 2,491.31 803.62
2015-03-31 -612.31 2,306.12 779.07
2014-12-31 -704.01 2,297.86 867.36
2014-09-30 -536.23 2,060.46 645.03
2014-06-30 -621.61 2,068.12 636.47
2014-03-31 -559.53 2,069.45 741.38
2013-12-31 -667.49 2,046.02 778.14
2013-09-30 -711.97 2,073.29 609.71
2013-06-30 -797.89 2,073.83 585.72
2013-03-31 -1,322.30 2,421.60 454.29
2012-12-31 -1,359.04 2,455.99 567.73
  • IQVIA Holdings's level of debt (173%) compared to net worth is high (greater than 40%).
  • IQVIA Holdings had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
  • Debt is not well covered by operating cash flow (10%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 2x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess IQVIA Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. IQVIA Holdings has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is IQVIA Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from IQVIA Holdings dividends. Estimated to be 0% next year.
If you bought $2,000 of IQVIA Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate IQVIA Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate IQVIA Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NYSE:IQV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NYSE:IQV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 5.00
2019-12-31 0.00 5.00
NYSE:IQV Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2014-10-30 0.000 0.000
2014-07-31 0.000 0.000
2014-05-01 0.000 0.000
2014-02-13 0.000 0.000
2013-10-31 0.000 0.000
2013-08-01 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as IQVIA Holdings has not reported any payouts.
  • Unable to verify if IQVIA Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of IQVIA Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as IQVIA Holdings has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of IQVIA Holdings's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess IQVIA Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can IQVIA Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. IQVIA Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of IQVIA Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ari Bousbib
COMPENSATION $16,461,779
AGE 57
TENURE AS CEO 2.6 years
CEO Bio

Mr. Ari Bousbib serves as Chairman and Chief Executive Officer at IQVIA Holdings Inc. since October 2016 and also serves as its President. He has been the Chairman, Chief Executive Officer and President of Quintiles IMS Holdings, Inc. since October 3, 2016. Mr. Bousbib served as the Chief Executive Officer of IMS Health Holdings, Inc. from September 2010 to October 2016 and also served as its President since September 2010. In 2014, he led the successful IPO of IMS Health. Prior to his appointment at IMS Health, he spent 14 years at United Technologies Corporation (UTC), the parent company of Otis Elevator Company, Carrier Corporation, UTC Power, UTC Fire & Security, Pratt & Whitney, Sikorsky Aircraft, where he held several senior leadership positions. He joined UTC in 1997 as Chief Strategy and Development Officer. Mr. Bousbib served as Corporate Executive Vice President and President of Commercial Companies at United Technologies Corp. from May 12, 2008 to September 1, 2010 and served as its Executive Vice President at UTC until September 1, 2010. He served as President of Otis Elevator Company, a subsidiary of United Technologies Corp., from April 2002 to May 2008. He served as an Executive Vice President and Chief Operating Officer of Otis Elevator Company from 2000 to 2002. He served as Vice President of Strategic Planning at United Technologies Corporation from April 1997 to January 2001 and Unit President from April 2002 to September 1, 2010, where he was responsible for strategic planning and corporate development functions. Mr. Bousbib served as Managing Director of The Strategic Partners Group from 1995 to 1997. Mr. Bousbib was a Partner of global management and technology consulting firm Booz Allen Hamilton since 1992, which he joined in 1987. He served as the Chairman at IMS Health Holdings, Inc. since December 2010 until October 3, 2016. He serves as a Director of Home Depot U.S.A., Inc. He has been an Independent Director of Home Depot, Inc., since November 2007 and a Director at Next Generation Network, Inc. since January 2000. He has been Director of Quintiles IMS Holdings, Inc. since October 3, 2016. He serves as a Director for Techmetrics, International Fuel Cells, Dow-UT and MyAircraft.com. He served as a Director at IMS Health since 2010 until October 3, 2016. He served as a Director of Best Buy Co., Inc. since August 23, 2006. He served as a Director of Zardoya Otis, S.A. He is a member of the Harvard Medical School Health Care Policy Advisory Council. In 2008, he as was appointed by the President of the United States to serve on the President’s Commission on White House Fellowships. Mr. Bousbib holds a Master of Science Degree in Mathematics and Structural Engineering from the Ecole Superieure des Travaux Publics, Paris and an MBA in Finance from Columbia University.

CEO Compensation
  • Ari's compensation has been consistent with company performance over the past year.
  • Ari's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the IQVIA Holdings management team in years:

2.6
Average Tenure
54
Average Age
  • The tenure for the IQVIA Holdings management team is about average.
Management Team

Ari Bousbib

TITLE
Chairman
COMPENSATION
$16M
AGE
57
TENURE
2.6 yrs

Mike McDonnell

TITLE
Executive VP & CFO
COMPENSATION
$3M
AGE
54
TENURE
3.4 yrs

Eric Sherbet

TITLE
Executive VP
COMPENSATION
$1M
AGE
54
TENURE
1.2 yrs

W. Staub

TITLE
President of Research & Development Solutions
COMPENSATION
$2M
AGE
55
TENURE
2.5 yrs

Kevin Knightly

TITLE
President of Information & Technology Solutions
COMPENSATION
$2M
AGE
57
TENURE
2.6 yrs

Manny Korakis

TITLE
Senior VP
AGE
44
TENURE
0.5 yrs

Jeff Spaeder

TITLE
Senior VP

Alejandro Martinez

TITLE
Chief Information Officer
TENURE
4.4 yrs

Andrew Markwick

TITLE
Vice President of Investor Relations

Marla Kessler

TITLE
Senior Vice President of Strategy
AGE
48
Board of Directors Tenure

Average tenure and age of the IQVIA Holdings board of directors in years:

2.6
Average Tenure
59
Average Age
  • The average tenure for the IQVIA Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ari Bousbib

TITLE
Chairman
COMPENSATION
$16M
AGE
57
TENURE
2.6 yrs

James Fasano

TITLE
Director
AGE
48
TENURE
2.6 yrs

Ron Rittenmeyer

TITLE
Director
COMPENSATION
$335K
AGE
71
TENURE
2.6 yrs

Todd Sisitsky

TITLE
Director
AGE
47
TENURE
2.6 yrs

John Leonard

TITLE
Lead Director
COMPENSATION
$326K
AGE
61
TENURE
0.8 yrs

John Connaughton

TITLE
Director
AGE
55
TENURE
11.3 yrs

Jonathan Coslet

TITLE
Director
AGE
54
TENURE
16.3 yrs

Mike Evanisko

TITLE
Independent Director
COMPENSATION
$310K
AGE
68
TENURE
9 yrs

John Danhakl

TITLE
Director
AGE
62
TENURE
2.6 yrs

Colleen Goggins

TITLE
Director
COMPENSATION
$312K
AGE
64
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
12. Mar 19 Sell Bain Capital, LP Company 08. Mar 19 08. Mar 19 -868,684 $140.80 $-122,310,707
12. Mar 19 Sell TPG Capital, L.P. Company 08. Mar 19 08. Mar 19 -4,044,480 $140.80 $-569,462,784
07. Dec 18 Sell Bain Capital, LP Company 04. Dec 18 04. Dec 18 -767,574 $123.72 $-94,964,255
06. Dec 18 Sell TPG Capital, L.P. Company 04. Dec 18 04. Dec 18 -3,573,545 $123.72 $-442,118,987
04. Dec 18 Sell Canada Pension Plan Investment Board Company 04. Dec 18 04. Dec 18 -1,582,194 $123.72 $-195,749,042
14. Sep 18 Sell John Danhakl Individual 13. Sep 18 13. Sep 18 -3,678 $126.92 $-465,170
14. Sep 18 Sell Leonard Green & Partners, L.P. Company 13. Sep 18 13. Sep 18 -409,555 $126.92 $-51,797,918
13. Sep 18 Sell John Danhakl Individual 11. Sep 18 12. Sep 18 -3,298 $126.89 $-411,680
13. Sep 18 Sell Leonard Green & Partners, L.P. Company 11. Sep 18 12. Sep 18 -367,172 $126.89 $-45,833,037
12. Sep 18 Sell Leonard Green & Partners, L.P. Company 07. Sep 18 07. Sep 18 -221,900 $126.63 $-28,099,197
06. Aug 18 Sell Robert Parks Individual 02. Aug 18 02. Aug 18 -871 $124.35 $-108,304
19. Jun 18 Sell Bain Capital, LP Company 15. Jun 18 15. Jun 18 -1,441,236 $103.00 $-148,447,308
19. Jun 18 Sell Canada Pension Plan Investment Board Company 15. Jun 18 15. Jun 18 -3,097,012 $103.00 $-318,992,236
19. Jun 18 Sell TPG Capital, L.P. Company 15. Jun 18 15. Jun 18 -6,716,253 $103.00 $-691,774,059
X
Management checks
We assess IQVIA Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. IQVIA Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is There Now An Opportunity In IQVIA Holdings Inc. (NYSE:IQV)?

The company's stock. … saw a double-digit share price rise of over 10% in the past couple of months on the NYSE. … As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock

Simply Wall St -

A Look At The Fair Value Of IQVIA Holdings Inc. (NYSE:IQV)

We generally believe that a company's value is the present value of all of the cash it will generate in the future. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model? … We're using the 2-stage growth model, which simply means we take in account two stages of company's growth

Simply Wall St -

How Do Analysts See IQVIA Holdings Inc. (NYSE:IQV) Performing In The Years Ahead?

IQVIA Holdings Inc.'s (NYSE:IQV) released its most recent earnings update in December 2018, whicha

Simply Wall St -

If You Had Bought IQVIA Holdings Stock Five Years Ago, You Could Pocket A 169% Gain Today

But on a lighter note, a good company can see its share price rise well over 100%. … One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). … IQVIA Holdings's earnings per share are down 7.0% per year, despite strong share price performance over five years.

Simply Wall St -

Should You Be Impressed By IQVIA Holdings Inc.'s (NYSE:IQV) ROE?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Our data shows IQVIA Holdings has a return on equity of 17% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is It Time To Consider Buying IQVIA Holdings Inc (NYSE:IQV)?

received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to $130.77 at one point, and dropping to the lows of $115.24. … A question to answer is whether IQVIA Holdings's current trading price of $117.73 reflective of the actual value of the? … Let’s take a look at IQVIA Holdings’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change

Simply Wall St -

Should We Be Delighted With IQVIA Holdings Inc's (NYSE:IQV) ROE Of 17%?

We'll use ROE to examine IQVIA Holdings Inc (NYSE:IQV), by way of a worked example. … That means that for every $1 worth of shareholders' equity, it generated $0.17 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

IQVIA Holdings Inc (NYSE:IQV): Time For A Financial Health Check

Investors pursuing a solid, dependable stock investment can often be led to IQVIA Holdings Inc (NYSE:IQV), a large-cap worth US$25.7b. … This article will examine IQVIA Holdings’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth. … Check out our latest analysis for IQVIA Holdings

Simply Wall St -

Why Did These Investors Just Divested From IQVIA Holdings Inc (NYSE:IQV)?

IQVIA Holdings's insiders have divested from. … Generally, insiders selling shares in their own firm sends a bearish signal … A research published in The MIT Press (1998) concluded that stocks following insider selling fell 2.7% compared to the market.

Simply Wall St -

Has IQVIA Holdings Inc's (NYSE:IQV) Earnings Momentum Changed Recently?

Examining IQVIA Holdings Inc's (NYSE:IQV) past track record of performance is a valuable exercise for investors. … Below, I will assess IQV's latest performance announced on 31 March 2018 and weigh these figures against its longer term trend and industry movements. … How Did IQV's Recent Performance Stack Up Against Its Past.

Simply Wall St -

Company Info

Description

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Details
Name: IQVIA Holdings Inc.
IQV
Exchange: NYSE
Founded: 1982
$26,365,164,101
197,240,698
Website: http://www.iqvia.com
Address: IQVIA Holdings Inc.
4820 Emperor Boulevard,
Durham,
North Carolina, 27703,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE IQV Common Stock New York Stock Exchange US USD 09. May 2013
DB QTS Common Stock Deutsche Boerse AG DE EUR 09. May 2013
LSE 0JDM Common Stock London Stock Exchange GB USD 09. May 2013
BMV IQV * Common Stock Bolsa Mexicana de Valores MX MXN 09. May 2013
Number of employees
Current staff
Staff numbers
58,000
IQVIA Holdings employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 02:59
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/15
Last earnings filing: 2019/05/02
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.